Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity by unknown
Tumor Irrmaunogenicity  Determines  the Effect  of B7 
Costlmulation  on T  Cell-mediated  Tumor Immunity 
By Lieping Chen, Patrick McGowan, Stephanie Ashe, 
Janet Johnston, Yiwen Li, Ingegerd Hellstr6m, 
and Karl Erik Hellstr6m 
From Bristol-MTers Squibb  Pharmaceutical Research Institute,  Seattlg  Washington  98121 
Summary 
A costimulatory signal through B7 to its counter-receptor CD28 on T  cells enhances T  cell 
activation. We have generated recombinant retroviruses containing cDNA for routine B7 and 
transduced a pand of murine tumor lines with varying immunogenicity to study the effect of 
B7 costimulation on antitumor immunity. In contrast to the progressive outgrowth of all wild- 
type (B7-)  tumors in unimmunized syngeneic mice, four immunogenic tumors, lymphoma 
RMA, EL4, mastocytoma P815, and melanoma E6B2,  regressed completely when transduced 
with the B7 gene. In contrast, four nonimmunogenic tumors, sarcomas MCA101,  MCA102, 
and Agl04,  and mdanoma B16,  remained tumorigenic after  transduction of the B7 gene. 
Immunization with B7-tranduced immunogenic tumors enhanced protective immunity and 
increased specific cytotoxic T lymphocyte (CTL) activity against the respective wild-type tumors 
as compared to  immunization with  nontransduced or  mock-transduced tumors.  Moreover, 
cocultivation of CTL with B7-transduced EL4 cells augmented the specificity of tumor-reactive 
CTL in long-term cultures. Treatment by injection of B7-transduced tumor cells cured 60% 
of mice with established wild-type EL4 lymphoma. In contrast, immunization with nonimmuno- 
genic tumors transduced with B7 did not provide protective immunity and did not increase specific 
CTL activity.  Our results  show that  tumor immunogenicity is critical  to  the outcome of 
costimulation of T  cell-mediated tumor immunity by B7. 
M 
any experimentally  induced animal tumors are immuno- 
genie., i.e., they express tumor-specific transplantation 
antigens as evidenced by their rejection after transplantation 
to syngendc animals immunized against the respective tumors 
(1). Other tumors are nonimmunogenic, i.e., they are not 
rejected  when similarly tested. 
Rejection of immunogenic tumors is primarily mediated 
by T  cells (1) with both CD8 + CTL and CD4 + Th ceils 
playing important roles (2, 3). Growing evidence indicates 
that the T ceils require at least two signals to become acti- 
vated (4, 5). Signal one is generated by the interaction be- 
tween an antigen-specific receptor on the T lymphocytes and 
antigenic peptide-MHC complexes on APCs, e.g., tumor 
ceils or macrophages. Signal two is delivered by costimula- 
tory molecules on the APCs through their counter-receptors 
on the T lymphocytes (4). Without costimulation, exposure 
of T  cells  to  an  antigen  may cause  unresponsiveness  or 
anergy (4). 
There are several molecules that can provide costimulation 
(3). Particular interest has recently been given to BT, which 
is the natural ligand for the CD28 and CTLA-4 counter- 
receptors on T  cells (6).  B7 is a member of the Ig super- 
family (7, 8) and is expressed on the majority of APCs, such 
as dendritic cells, activated macrophages, and activated B cells. 
The interaction of B7 with CD28/CTLA-4 results in an in- 
creased stability ofmRNA for several lymphokines, including 
IL-2 (for a review see reference 6). Treatment of mice with 
a CTLA4Ig fusion protein, which binds to B7 with high 
aff~ty, strongly inhibits T ceil--dependent antibody responses 
(9), and makes possible the long-term acceptance of xeno- 
grafted pancreatic islets (10). 
Costimulation of T  cells by B7 also plays an important 
role in eliciting antitumor immunity, and  an inadequate 
costimuhtion has been suggested to contribute to the progres- 
sive growth of tumors in immunocompetent host (11, 12). 
We have previously shown that an immunogenic  mouse mela- 
noma E7C3, which contains the tramfected E7 gene of human 
papillomavirus (HPV)l-16, grew progressively in immuno- 
competent syngeneic mice, but no longer grew after trans- 
fection with the murine B7 gene, whereas its growth in im- 
I Abbm,iations used in this paper:  HPV,  human papillomavirus; Nh"rD, 
minimal tumorigenic dose. 
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Volume  179  February 1994  523-532 munodeficient (nu/nu) mice was not impaired. The immune 
response was primarily mediated by CD8 + T  cells and the 
rejection of tumors did not require the expression of B7 on 
the target ceUs. Treatment by injection of B7 + E7C3 cells 
cured 40% of mice with micrometastasis in their lungs es- 
tablished from intravenously injected E7C3 wild-type cells 
(12). Townsend and Allison (13) reported that the mouse mda- 
noma K1735,  after transfection with the B7 gene, was re- 
jected when transplanted into immunocompetent syngeneic 
mice, and that  these mice rejected a subsequent transplant 
of wild-type KI735 mdanoma.  Baskar et al.  (14) generated 
a protective immunity towards the mouse Sal sarcoma subse- 
quent to coexpression of B7 with truncated MHC class II 
molecules that  lacked the cytoplasmic domain. 
Providing B7 costimulation does not always lead to aug- 
mentation of tumor immunity, however. As was shown pre- 
viously in our experiments, mouse melanoma K1735-M2 did 
not become immunogenic by transfection of B7 (12), a finding 
distinct  from that  obtained by Townsend and Allison (13) 
whose experimental conditions were slightly different. Like- 
wise, B7-transfected mouse sarcoma Sal did not regress in 
the absence of cotransfected MHC class II molecule (13). 
Based on the two signal theory of T cell activation (15-17), 
ef~cient induction of T  cell immunity against a tumor re- 
quires, first, the existence of tumor antigen(s) which can be 
processed, transported to, and presented by MHC class I and/or 
II molecules on the APCs, and second, suffident costimula- 
tory molecule(s) on the tumor cells or other APCs. A predic- 
tion of this theory is that, in the presence of costimulatory 
molecttles, the expression of tumor antigen and its presenta- 
tion  will be factors limiting  the generation  of effective T 
cell-mediated tumor immunity (11). Anomalies exist in an- 
tigen processing and presentation,  as evidenced by tumors 
with downregulated MHC class I expression (18) or defec- 
tive MHC-encoded proteasome components (19). Therefore, 
transfection of tumor cells with B7 may be used to probe 
the existence of tumor antigen and/or the ability of tumor 
cells  to present  such antigen. 
In this report,  we describe the effect of transduction  of 
the B7 gene into a variety of tumors with high, low, or non- 
detectable immunogenicity when tested in tumor rejection 
assays. Rctroviruses containing the murine B7 gene were pre- 
pared and used to transduce the B7 gene into  the various 
tumors, whose growth in immunocompetent, syngeneic mice, 
as well as their capacity to augment T  cell-mediated tumor 
immunity  in vivo and in vitro was then investigated. 
Materiah  and Methods 
M/c~  Female  C3H/HeN and BALB/c (nu/nu) mice, 4-8-wk- 
old, were bought from Harlan Sprague Dawley, Inc. (Indianapolis, 
IN). Female C57BL/6, 4-8-wk-old,  were purchased from Taconic 
Farms Inc. (Germantown, NY). Female DBA/2 mice, 4-6-wk-old, 
were purchased from The Jackson Laboratory (Bar Harbor, ME). 
Cell Lines.  The tumor lines used for this study are listed in 
Table 1. The EL4 and TIMI.4 lymphomas and the B16 melanoma 
are of C57BL/6 (H-2  b) origin,  and the P815 mastocytoma  and 
L5178Y lymphoma came from DBA/2 (H-2  a) mice. YAC-1 is a 
NK-sensitive lymphoma. A20, ABE-8.1/2, CH1, RAW8.1, WEHI- 
231, and 2PK-3 are B lymphoma lines. The Meth A fibrosarcoma 
originated in BALB/c (H-2a). All these tumor lines were obtained 
from American Type Culture Collection ([ATCC] Rockville, ME)). 
RMA lymphoma (from Dr. P. Hrglund, Karolinska Institute, Stock- 
holm,  Sweden) is of C57BL/6 origin  (20), as are 3-Methylchol- 
anthrene-indoced sarcomas MCA101, MCA102 (21), and colon car- 
cinoma MC38 (22) (from Dr. J. J.  Mulr,  the National  Cancer 
Institute, National Institutes of Health, Bethesda, MD). The K1735- 
M2 melanoma (23) (from Dr. I.J. Fidler, M.D. Anderson Cancer 
Research Center, Houston, TX), its HFV-16 E6 transfectant E6B2 
(24), and the Agl04 sarcoma (25) (from Dr. H. Sehreiber, Univer- 
sity of Chicago,  Chicago,  IL) are of C3H/HeN (H-2  k) origin. 
The M109 lung carcinoma (from Dr.  P. Wallace, Bristol-Myers 
Squibb Pharmaceutical Research Institute, Seattle, WA) came from 
a BALB/c (H-2  d) mouse  (26). Once acquired, all tumors  were 
briefly expanded in vitro and frozen to decrease experimental varia- 
tion.  All cells were maintained in vitro at 37~  in DMEM con- 
taining 10% FCS (HyClone Laboratories, Logan, UT) for no longer 
than  1 mo before in vivo experiments. 
Plasraid Construction.  A DNA fragment encoding the entire open 
reading frame of murine B7 was amplified by PCR from phsmid 
pmB7 (12) or by reverse transcription-coupled  PCR from RNA 
prepared from Con A-activated murine spleen cells (27). The sense 
primer  (  5  'CGATGACGATCGCCTCGAGAAGCTTAIGC~TT- 
GAAATIGT-3')  consists of an oligonuclentide corresponding  to 
1-15 nucleotides of murine B7 plus a 6-bp consensus sequence and 
a restriction  site for XhoI. The antisense primer  (5'-GACTAG- 
AGCTATCCTC GAGCTAAAGGAAGAC  GGTCTGTTC-3 ') cor- 
responds to 901-921 nucleotides of routine B7 plus a site for XhoI. 
PCR. was performed as described (27) and the PCR product was 
directly cloned into the pCRTMII vector (Invitrogen,  San Diego, 
CA) and subcloned into the retroviral vectors pLXSN and pLNSX 
(28) (from Dr. D. Miller, Fred Hutchinson Cancer P,~e.arch Center, 
Seattle, WA). The structures of the resulting constructs pLXSNmB7 
and pLNSXmB7  are shown (see Fig. 1). 
Retrovims Preparation and Infection of Turaor Lines.  Recombinant 
viruses were generated as described previously (24, 29). Briefly, 
plasmids were a routine B7 insert were transfected by dectropora- 
tion into the PA317 amphotropic packaging line, and viruses pro- 
duced from the PA317 cells were used to infect the ~-2 ecotropic 
packaging cell line in the presence of 8 p.g/ml of polybrene (Sigma 
Chemical Co., St. Louis, MO). After infection, the r  cells were 
selected in DMEM containing  G418 (1 mg/ml) (GIBCO BRL, 
Gaithersburg,  MD). Viruses generated from G418-resistant lines 
of ~-2 were used to infected tumor lines according to previously 
described procedures (24, 29). CeU lines infected with the recom- 
binant retroviruses were cloned by limiting  dilution or sorted by 
FACS  ~ (Becton Dickinson & Co., Mountain View, CA) and selected 
for expression of BT. All lines were tested by a marker rescue assay 
(30) and found to be free of helper virus. The pLXSN and pLNSX 
vectors without B7 insert were used for the preparation of mock 
viruses by the same procedure. 
FACS  ~ Analysis.  For detection orB7 expression, cells were in- 
cubated for 30 rain at 4~  with either a control lg, chimeric L6, 
or with CTLA4Ig (9, 12) at 10/~g/ml.  They were then washed 
and incubated or an additional I h at 4~  with FITC-conjugated 
goat anti-human Ig C'y serum (Tago Inc., Burlingame, CA). Stained 
cells were analyzed by FACS  |  For detection of MHC class I mole- 
cules, the following FITC- or biotin-hbded mAbs were used: AF3- 
12.1 for H-2Kt; AF6-88.5 for Kb; KH95 for Db; SFI.1 for Ka; and 
34-2-12 for D a (Pharmingen, San Diego, CA). Purified mAb from 
15-5-5S hybridoma  (ATCC) was used for staining of H-2D  k. 
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for a CTL response to tumor cells have been described (24)  and 
were used with minor modification. Briefly,  mice were injected 
subcutaneously with mock- or B7-transduced cells. Tumor nodules 
were removed surgically at day 10.2 wk after injection, spleen cells 
were prepared and cocultivated with '),-irradiated tumor cells (5,000 
rad) in 24-well plates (Costar, Cambridge, MA) for 5 d. For the 
generation  of long-term T  cells  lines,  spleen cell  cultures  were 
restimulated every 7-10 d in the presence of human recombinant 
IL-2 (Cetus Corp., Emeryville, CA) at 10 U/ml as described (24). 
The cytolytic activity of lymphocytes was examined in a standard 
4-h StCr-release assay with different E/T ratios as indicated in the 
figures. 
Animal Studies.  Tumor cells were injected into the shaved right 
back of mice in a 0.1-ml volume via a 26-gauge needle and using 
a 1-ml syringe. The minimal tumorigenic doses (MiTD) of tumor 
cells required for outgrowth in 100% of syngeneic mice were first 
determined (see Table 2) and were used except when indicated differ- 
ently in the legends of the figures and tables. The mice were scored 
for tumor growth once a week and tumor size was documented 
by measuring two perpendicular diameters in millimeters using a 
caliper. Two protocols were used for immunization: (a) Mice were 
injected with irradiated (5,000 rad) tumor cells and subsequently 
challenged with wild-type tumor calls 3 wk later.  The B7 + EL4 
and B7*  P815 lines  were not irradiated as they regressed in im- 
munocompetent mice. (b) Mice were injected with liver tumor cells 
and surgically removed tumor nodules at day 10 after injection and 
2 wk after tumor removal, the mice were challenged with wild- 
type tumor cells. 
Results 
Expression of B7 in Murine  Tumor Lines.  The expression 
of B7 on the surface of cells from 18 routine tumor lines de- 
rived from different tissues, including mdanomas, sarcomas, 
lymphomas, carcinomas, and a mastocytoma, was examined 
by FACS  |  using CTLA4Ig immunostaining. Four out of six 
B  cell lymphoma lines were positive,  whereas B7 was not 
detectable  in  any of the  other  tumors  (Table  1). 
Determination of Tumor Immunogenicity.  Eight B7-  tumor 
lines were selected for further experiments based on their im- 
munogenicity as determined by tumor immunization and chal- 
lenge assay as described in the reports listed in Table 2. The 
tumorigenicity and MiTD of each line were determined by 
s.c. inoculation of serially diluted tumor cell suspensions into 
syngeneic mice. A single injection of irradiated RMA or E6B2 
at dose of lx  MiTD  or  10 x  MiDT completely protected 
syngeneic mice from challenge  of the respective tumors  at 
dose of lx  MiTD.  The same injection of EL4 or P815 did 
not provide any significant protection against subsequent chal- 
Table  1.  Expression of B7 on Murine Tumor Lines 
Cell line  Tissue type  Strain  Transformation  B7 expression* 
K1735  Melanoma  C3H/HeN  UV  - 
B16  Melanoma  C57BL/6  Spontaneous  - 
MCA101  Fibrosarcoma  C57BL/6  Chemical carcinogen  - 
MCA102  Fibrosarcoma  C57BL/6  Chemical carcinogen  - 
Agl04  Fibrosarcoma  C3H/HeN  Spontaneous  - 
MethA  Fibrosarcoma  BALB/c  Chemical carcinogen  - 
EL4  T  Lymphoma  C57BL/6  Chemical carcinogen  - 
R/VIA  T  Lymphoma  C57BL/6  Virus  - 
L5178Y  T  Lymphoma  DBA/2  Chemical carcinogen  - 
A20  B  Lymphoma  BALB/c  Spontaneous  - 
ABE-8.1/2  B Lymphoma  BALB/c  Virus  - 
CH1  B Lymphoma  B10.H-2'H-4  b  Unknown  +  + 
RAW8.1  B Lymphoma  BALB/c  Virus  + 
WEHI-231  B Lymphoma  BALB/c  x  NZB  Chemical carcinogen  + 
2PK-3  B Lymphoma  BALB/c  Chemical carcinogen  +  + 
P815  Mastocytoma  DBA/2  Chemical carcinogen  - 
MC38  Carcinoma  C57BL/6  Chemical carcinogen  - 
M109  Carcinoma  BALB/c  Spontaneous  - 
* The expression of B7 was determined by indirect immunofluorescence  and FACS  ~ analysis by using CTLA4Ig as described in Materials and Methods. 
(+) 2-10-fold above background fluorescence; (+ + ) >10-fold above background fluorescence. 
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H-2  Transplantation  MiTD  Reference 
Cell line  type  immunogenicity  ( x 104)  no. 
RMA  b  + *  0.1'  20 
E6B2  k  +  200.0  24 
P815  d  +  5.0  40 
EL4  b  +  5.0  41, 42 
MCA101  b  -  20.0  21 
MCA102  b  -  20.0  21 
Agl04  k  -  100.0  25 
B16  b  -  10.0  31 
* Transplantation immunogenicity  is recorded  based on results from im- 
munization and challenge  experiments as described in the publications 
indicated and confirmed  by our own studies. 
MiTD was determined as described in Materials and Methods. 
lenge. However, complete protection against the outgrowth 
of EL4 and P815 in syngeneic mice could be achieved if mul- 
tiple boosts were performed after the initial immunization. 
Therefore, these four tumors were scored as immunogenic. 
Four other tumors, i.e., MCA101, MCA102, Agl04, and B16 
were nonimmunogenic in similar tests (Table 2). These results 
agree with the published immunogenicity of  the various tumor 
lines. 
Transduction of the Murine B7 Gene into B7-  Tumor Lines. 
Two vectors containing the murine B7 gene were used to 
prepare retroviruses (Fig.  1). In pLXSNmB7, the B7 open 
Xho I 
,'+  i  F 
Xho  I  PA 
pLXSNmB7 
Hind III  PA 
pLNSXmB7 
Figure L  Structure of retroviral vectors containing the murine B7 
cDNA. 
reading frame is driven by the routine leukemia virus en- 
hancer-promoter LTR. This vector also contains the neomycin- 
resistance gene (neo) for drug selection. The second vector, 
pLNSXmB7, has the same backbone as pLXSNmB7 except 
that the SV40 promoter is used for driving B7 and the LTR 
promoter for neo. High titer stocks of ecotropic virus were 
prepared as described (24, 29). The tumor lines listed in Table 
2 were transduced by the pLXSN-based retrovirus except for 
P815 and B16 which were transduced by the pLNSX-based 
retrovirus because of a low efficiency of transduction by the 
pLXSN-based retrovirus in these two lines. 
Tumor lines infected with retrovirus were propagated for 
7-10 d in selection medium and cloned. Clones obtained from 
each line were screened by FACS  |  for expression of B7 by 
binding of CTLA4Ig. Three-to-five  clones from each tumor 
line which stably expressed highest B7 on their surface were 
picked for expansion. After in vivo tumorigenicity tests (see 
Fig. 3), one done from each line was selected for further ex- 
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Figure 2.  (.4.)  Expression  of B7 
on transduced tumor fines. Cells 
were stained  with either  CTLA-41g 
(solid line) or the control  Ig chimeric 
L6 (dashed line) followed  by FITC- 
conjugated  goat anti-human Ig C3' 
serum as described  in Materials  and 
Methods. A total  of  5,000 cells  was 
analyzed for each sample. (B) Ex- 
pression of MHC class I molecules 
on transduced tumor lines. The 
mock-transduced (Mock) or  B7- 
transduced (B7  +) cells were stained 
with  control mAb  (dotted line), 
FITC-, or biotin-hbeled  mAbs to 
H-ZK (dashed line) or H-2D (solid 
line) and subjected to FACS  |  anal- 
)'sis. A total of 5,000 cells was ana- 
lyzed for each sample. 
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Figure  3.  Growth of tumors  induced by mock-transduced and B7 + 
tumor cells in syngeneic mice. Mice were injected subcutaneously with 
the indicated cells at M~D (see Table 2). Tumor size was assessed weekly 
by measuring perpendicular diameters with a caliper. The experiments  were 
terminated when the tumors reached 20-30 mm in diameter, severe  ulcer- 
ation and bleeding had developed, or the mice had died. The results are 
expressed as mean diameter (in millimeters) of tumors from groups of five 
mice each. Error bars represent the standard deviation of the mean. Similar 
results were obtained in at least three experiments with each cell line. 
periments. The levels of B7 expression on the selected tumor 
dones  are summarized in Fig.  2  A. 
The expression of MHC  class I molecules on the various 
tumor lines was also examined with  or without  B7 trans- 
duction.  EL4,  P815,  RMA,  and Agl04  all expressed high 
level of MHC class I molecules. On the other hand, expres- 
sion of MHC class I was either low or not detectable on the 
other four tumor lines, i.e., E6B2, MCA101, MCA102,  and 
B16. There are no significant changes on the level of MHC 
I  expression by B7  transduction  (Fig.  2 B). 
Transduction of the B7 Gene Eliminates the Tumorigenicity of 
Irnmunogenic Tumors but Does Not Affect Nonimmunogenic 
Tumors.  B7 § cells from each of the eight transduced tumor 
lines  were  injected  subcutaneously  into  syngeneic,  im- 
munocompetent  mice, and mock-transduced cells from the 
respective  tumors  served  as  controls.  The  B7-  control 
tumors grew progressively in all mice inoculated. In contrast, 
four B7 + immunogenic tumors, i.e., RMA, E6B2, EL4, and 
P815, either did not grow at all (RMA) or completely regressed 
after a transient growth (E6B2,  EL4, and P815) in the mice 
(Fig.  3, Table 3). B7 + clones from RMA,  E6B2,  and P815 
grew progressively in BALB/c nude mice, indicating that T 
cell-mediated immunity was responsible for their rejection 
in immunocompetent  mice.  On  the other hand,  B7 + EL4 
regressed also in the nude mice (Table 3). No regressions were 
seen in immunocompetent  mice injected  with  B7 +  clones 
derived from the nonimmunogenic  tumors that were non- 
immunogenic. 
B7-transduced  Immunogenic Tumors, but Not Nonimmunogenic 
Tumors, Can Induce Systemic Immunity to Wild-type Tumors. 
The  ability  of both  immunogenic  and  nonimmunogenic 
tumors to induce systemic immunity was examined. Preim- 
munization  of mice by a  single injection  of irradiated  EL4 
or P815 did not protect them from chatlenge with the respec- 
tive wild-type calls. In contrast, the same dose of nonirradi- 
ated B7 + EL4 or P815 cells completely protected mice from 
challenge with the respective wild-type tumors (Fig.  4 A). 
To exclude that this difference is due to a radiation effect on 
Table  3.  Tumorigenicity  of BT-transduced Tumor Lines in Syngeneic and in BALB/c (nu/nu) Mice 
Tumor incidence" 
Syngeneic mice*  BALB/c nude  mice 
Cell line  WT  Mock  B7 §  WT  Mock  B7 § 
RMA  ND  10/10  0/10s  ND  ND  ND 
E6B2  18/20  ND  0/10s  5/5  10/10  10/10 
P815  10/10  10/10  0/10s  ND  10/10  10/10 
EL4  20/20  20/20  0/30s  ND  10/10  0/10s 
MCA101  15/15  15/15  15/15  ND  5/5  5/5 
MCA102  15/15  10/10  14/14  5/5  5/5  5/5 
Agl04  15/15  15/15  15/15  ND  5/5  5/5 
B16  10/10  10/10  15/15  ND  ND  ND 
* Mice were injected with tumor cells subcutaneously at 1 ￿  MiTD (RMA at 100 x  MITD). Tumor size was assessed by measuring two perpendicu- 
lar diameters in millimeters by a caliper weekly for each animal. Mice with tumors <2 mm in diametcr at week 6 after injection were scored as negative. 
t Mouse strains syngeneic to the corresponding tumor lines are listed in Table 1. (WT) wild type; (Mock) mock transduced; (B7 +) B7-transduced 
tumor cells. 
$ Significantly different from the WT and Mock groups  (p <0.05). 
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Figure  4.  B7 + immunogenic tumors, but not nonimmunogenlc tumors, induce protective immunity against wild-type tumors. Mice were injected 
with (.4) HBSS, irradiated,  mock- or B7-transduced tumor ceils (B7 + EL4 and B7 + P815 were nonirradiated)  intraperitoneally at 2x  MiTD. 3 wk 
later, the mice were challenged subcutaneously in the right back with the respective wild-type tumor cens at lx  MiTD. (/3) Alternatively, all mice 
were also injected with live tumor cells.  10 d  later,  tumor nodules were removed surgical]),.  2 wk after tumor removal, mice were challenged with 
wild-type tumor cells at lx  1Vh'TD. "lhmor size was assessed  weddy by measuring perpendicular diameters with a caliper.  The results are expressed 
as mean diameters (in millimeters) of tumors  from groups of five mice. Error bars represent the standard  deviation of the mean.  The same results 
were obtained in two experiments with each cell line. 
the wild-type EL4 and P815 cells, experiments were also per- 
formed in which mice were immunized by s.c. injection of 
live tumor ceils that were either B7 + or B7- followed, 10 d 
later, by surgical removal of the tumor nodules (Fig.  4 B). 
The results were similar. No recurrence was seen in mice im- 
munized with B7 + cells during a follow-up period of 3 mo 
after challenge. Preimmunization with B7 + clones from the 
four  nonimmunogenic  tumors,  i.e.,  from  B16,  Agl04, 
MCA101, or MCA102, did not confer any protective immu- 
nity against challenge with  the respective wild-type cells 
(Pig.  4). 
We also investigated whether immunization with B7 + 
cells could be used to treat already growing wild-type tumors 
using the EL4 lymphoma, which was the most aggressive 
of our four immunogenic tumors. Mice were injected s.c. with 
wild-type EL4 and were repeatedly injected intraperitoneaUy 
with B7 + EL4 cells starting 4  d  after tumor inoculation. 
This treatment cured 60% of mice (Fig.  5), whereas injec- 
tion of irradiated wild-type or mock-transduced EL4 cells 
did not affect the progressive growth of the EL4 lymphoma. 
B7 + Immunogenic Tumors, but Not Nonimmunogenic Tumors, 
Are Superior to B7-  Tumors to Augment  the Antitumor Re- 
sponse and Specificity of CTL.  To test whether the increased 
immunogenicity of tumors transduced with B7 correlated 
with an increased CTL activity, we compared the ability of 
B7 + and B7-  cells from mastocytoma P815 and lymphoma 
EL4 to induce tumor-specific CTL as assayed in vitro. Mice 
were immunized by injection of either B7- or mock-transduced 
cells followed by surgical removal of tumor nodules 10 d after 
injection. Splenocytes were harvested and further stimulated 
in vitro by cocultivation with irradiated wild-type ceils. Sub- 
sequently, they were tested for CTL activity in a standard 
SZCr-release assay. Mice were also immunized according to 
an alternative method, i.e., by the injection of nonirradiated 
B7 + or irradiated mock-transduced cells. Similar results were 
observed by both immunization methods: mice immunized 
by B7 + cells  generated significantly higher CTL  activity 
against the respective wild-type tumor cells than mice im- 
munized by B7-  cells (Fig.  6).  The CTL from B7 + EL4- 
immunized mice were tumor specific in that they did not 
lyse syngeneic, Con A-induced spleen blasts, syngeneic TIMI.4 
lymphoma cells, or aUogeneic P815 cells (data not shown). 
Similar results were obtained in the P815 tumor model. In 
contrast, immunization with B7-transduced MCA102 or B16 
did not induce any specific CTL response to the corresponding 
wild-type tumors (Fig.  6). 
T cell lines were generated by repeated stimulation with 
either irradiated B7 + or B7-  EL4 cells in order to examine 
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Figure  5.  B7 + EL4 cells induce systemic immunity against existing 
wild-type tumors. C57BL/6 mice, five per group, were injected subcutane- 
ously with 5  x  104 wild-type EL4 tumor cells. Mice were then treated 
4 d later by i.p, injection with I-IBSS, irradiated, mock.transduced or B7 + 
EL4 at 5  x  10 s. The same injections were subsequently repeated seven 
times at 5 d intervals. Tumor size was assessed weekly by measuring per- 
pendicular diameters with a caliph. The ~eriments wr  terminated when 
the tumors reached 20-30 ram in diameter, severe ulceration and bleeding 
had devdotugl, or the mice had died. The results are expressed by tumor 
size of individual mouse.  The same results we~ obtained in two other 
experiments. 
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Figure 6.  Comparison  of CTL activity  generated  fi'om  mice  immunized 
with either B7- or mock-transduced  tumor cells. The mock (O) or B7- 
transduced tumor cells (0) at 10  6 were injected  subcutaneously  into syn- 
geneic mice. 10 d later, tumor nodules  were removed surgically.  Spleen 
cells were  prepared 14 d after  injection,  and were  cocultivated  with 3,-irra- 
diated wild-type  cells for 5 d. CTL activity  against  stCr-hbded wild-type 
cells was measured as described in Materials and Methods. There are 
significantly  differences  between  mock and B7 + groups in every  E/T ratio 
(t, <o.o5). 
whether the presence  of B7 on the stimulator cells would 
augment a tumor-specific cytolytic activity. In both cases, 
irradiated EL4 cells were used for stimulation of the T cells 
every 7-10 d in the presence of a low dose of IL-2 (10 U/ml). 
1 mo later, the T cell lines were tested for phenotypic markers 
and assayed for specific lytic activity towards wild-type EL4 
cells.  In both types of cultures,  :>95%  of the cells  were 
CD8 + , and they were highly cytolytic for EL4 cells but did 
not lyse the syngeneic TIMI.4 lymphoma line, when tested 
in a standard StCr-release assay (Fig. 7). However,  the T cells 
stimulated with B7- EL4 had high NK activity as demon- 
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Figure  7.  Specificity  of CTL line to EL4 tumor cells. B7-traneduced 
EL4 cells, 10  ~ per mouse, were injected subcutaneously  into C57BL/6 
mice. Spleen cells were prepared 14 d after injection  and were repeatedly 
stimulated in vitro with ~/-irradiated, mock-transduced  EL4 cells (open 
columns) or with B7 + EL4 cells (solid columns) every 7-10 d in the pres- 
ence of  irradiated  syngeneic  spleen  cells and 10 U/m1  of  human  IL-2  (cotus 
Corp.). CTL activity  against stCr-labeled target  cells was measured  as cle- 
scribed in Materials  and Methods.  This assay  was done at passage 8. E/T 
ratio -  0.1. 
strated by the lysis of NK-sensitive YAC-1 cells, whereas T 
cells  stimulated with B7 +  EL4 did not  (Fig.  7).  Several 
CD8 +  CTL  clones,  which  are  K b restricted  and  highly 
specific for EL4, have recently been established from the T 
cell lines stimulated with B7 + EL4 (Chen, L., unpublished 
data). These results suggest that antigen presentation together 
with B7 costimulation augments the specificity of antitumor 
CTL maintained in vitro. 
Discussion 
Our results indicate that the immunogenicity of tumors, 
as determined by immunization and challenge experiments, 
is critical to the effect of B7 costimulation on tumor immu- 
nity. The capacity of tumor antigens to induce immune re- 
sponses, even when weak, could be amplified by the expres- 
sion of B7  in tumors  so  as  to  preclude their  growth in 
syngendc, immunocompetent hosts. In contrast, nonimmuno- 
genic tumors continued to grow progressively after transfer 
of the B7 gene. These data support the view that both an 
antigen-specific signal I and a nonspecific, costimulatory signal 
2 are required for the amplification of T  cell immunity. 
A single injection of syngeneic mice with B7 + , but not 
with B7-,  EL-4, or P815 cells protected them from chal- 
lenge with the respective wild-type cells (Fig. 4), indicating 
that a weak immune response against tumor antigens was 
amplified.  In these experiments, the B7 + tumors were ei- 
ther allowed to form tumor nodules that regressed  within 
a 2-4-wk period, or such nodules were surgically removed 
at day 10 after inoculation. The latter procedure allowed for 
a better comparison since both the B7 + and B7-  tumors 
had grown to approximately the same size. 
Similar to what we have reported for the highly immuno- 
genic E7C3 line (12), transfer of  B7 into tumor cells increased 
their ability to induce a strong, tumor-specific cytolytic re- 
sponse mediated by CD8 + T cells (Fig. 6). The finding that 
wild-type EL4 and P815 cells were effectively lysed by CTL 
in vitro may explain why a systemic immune response to- 
wards wild-type tumors was seen in vivo.  Furthermore, a 
therapeutic effect, causing the regression of small, established 
tumors, was seen in mice bearing wild-type EL4 cells and 
subsequently treated by injection of the respective B7 + cells. 
These results, obtained with tumors of weak immunogenidty, 
extend our previous findings using the highly immunogenic 
E7C3 line (12). 
It is noteworthy that the degree of  NK cell reactivity against 
YAC-1 target cells was much less when the CTL had been 
cocultivated with B7 + EL4 cells than when B7-EL4 cells 
were  used  (Fig.  7).  Since  highly specific reactivity of in 
vitro-expanded polyclonal T cells is desirable in adoptive cel- 
lular immunotherapy, the fact that sensitization with tumor 
cells expressing B7 augments CTL activity in vivo,  as well 
as CTL specificity as assayed in vitro, should be taken into 
account. 
We found that B7-transduced EL4 regressed  in BALB/c 
nude mice (Table 3), as well as in NK-deficient beige mice, 
and that they were resistant to NK cell-mediated lysis in vitro 
(Chen, L., unpublished data). Regression started 7-10 d after 
529  Chen et al. a transient  tumor growth (Fig.  3),  suggesting that  it was 
due to a host response. A possible explanation of the regres- 
sion seen in nude mice is that B7-transduced EL4 may pro- 
duce some cytokines which induce an antitumor  response. 
The finding that transduction of B7 into nonimmunogenic 
tumors failed to make them immunogenic can have several 
explanations.  It is possible that  nonimmunogenic  tumors, 
such as the four studied by us, either lack molecules that can 
serve as tumor antigens recognized by T cells, or are deficient 
in the processing, transportation, or presentation of such mol- 
ecules, i.e.,  that  the tumor cells do not deliver signal  1.  It 
is relevant, therefore, that MHC dass I molecules are unde- 
tectable in B16, MCA101,  and MCA102 (31,  32,  and Fig. 
2 B) and that  Tanaka  et al.  (31) could induce a protective 
immunity against challenge with wild-type B16 by immuni- 
zation with B16 cells transfected with the MHC dass I K b 
gene. Likewise, in vitro treatment of MCA101 sarcoma cells 
by IFN-3' (32) or transfection by IFN-3, cDNA (33), which 
upregulate  the expression of MHC class  I,  enhanced their 
sensitivity to lysis by CTL in vitro and induced the infiltra- 
tion of tumors by CD8 + lymphocytes in vivo; systemic im- 
munity against tumors was not examined, however. Further- 
more, Dranoffet al. (34) have recently reported that B16-F10 
melanoma cells transduced with a gene encoding GM-CSF 
could elicit protective immunity against challenge with wild- 
type B16-F10. The latter finding  may be explained by the 
production of some cytokines or costimulatory molecules other 
than B7 induced by GM-CSF. Taken together,  these results 
suggest that lack of immunogenicity of B16 and MCA101 
was not related to the absence of putative tumor rejection 
antigens and one may speculate that coexpression of B7 with 
either MHC class I molecules or IFN-3, will provide the double 
signaling needed for effective T  cell activation against some 
nonimmunogenic  tumors. 
We like to point out, however, that the in vitro expression 
of MHC class I molecules as detected by FACS  |  analysis  is 
not  always a reliable indicator  of tumor  immunogenicity. 
Whereas the nonimmunogenic Agl04 tumor expresses a high 
level of MHC class I molecules, two of our highly immuno- 
genic tumor lines,  E6B2 (Fig.  2 B) and E7C3 (12) displayed 
low or undetectable levels of MHC class I, a finding which 
we have discussed previously (12). 
It is also possible that costimulatory molecules other than 
B7 or B7-1ike molecules, such as intercellular adhesion mole- 
cules (ICAMs), vascular cell adhesion molecule 1 (VCAM-1), 
lymphocyte function-associated antigen 3 (LFA-3) and heat- 
stable antigen (HSA), are also needed to induce the rejection 
of some neoplasms since greater CD4 + T cell responses have 
been seen when coexpressing ICAM-1  (35),  HSA (36) or 
VCAM-1 (37) with B7 on APCs. This possibility is also sug- 
gested by the fact that some B lymphomas of human (7) and 
mouse origin (Table  1) express both high levels of B7 and 
MHC class  I  antigens. 
Although it remains controversial to what extent human 
cancers are immunogenic (1), T  cell-mediated responses to 
human tumor cells (38), and in some cases, to well-defined 
human tumor antigens, such as the MAGE antigen of mela- 
nomas, have been demonstrated (39). Therefore, augmenta- 
tion of T  cell costimulation by transfer of the B7 gene may 
be therapeutically beneficial in selected human cancers.  Fur- 
ther investigations in which genes encoding B7 and/or other 
costimulatory molecules,  as well as genes encoding MHC 
class I molecules, are transduced into tumor cells, will prob- 
ably extend the group of murine and human tumors to which 
rejection responses can be obtained. 
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